Last reviewed · How we verify
Zonisamide CR and Bupropion SR — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Zonisamide CR and Bupropion SR (Zonisamide CR and Bupropion SR) — Orexigen Therapeutics, Inc.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Zonisamide CR and Bupropion SR TARGET | Zonisamide CR and Bupropion SR | Orexigen Therapeutics, Inc | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Zonisamide CR and Bupropion SR CI watch — RSS
- Zonisamide CR and Bupropion SR CI watch — Atom
- Zonisamide CR and Bupropion SR CI watch — JSON
- Zonisamide CR and Bupropion SR alone — RSS
Cite this brief
Drug Landscape (2026). Zonisamide CR and Bupropion SR — Competitive Intelligence Brief. https://druglandscape.com/ci/zonisamide-cr-and-bupropion-sr. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab